Bevacizumab dosing strategy in paediatric cancer patients based on population pharmacokinetic analysis with external validation.

ABSTRACT:

Aim

The aim of the present study was to evaluate the pharmacokinetics of bevacizumab and various dosing strategies for this agent in paediatric patients.

Methods

Data were collected from 232 paediatric patients (1971 concentrations) in five studies, with a wide range of age (0.5-21 years), body weight (BWT; 5.9-125 kg), and regimens (5-15 mg kg(-1) biweekly or triweekly). Data from 152 patients (1427 concentrations) and 80 patients (544 concentrations) were used for model building and external validation, respectively. Steady-state exposure was simulated under BWT-based, body surface area (BSA)-based, ideal body weight (IBW)-based, and tier-based doses. NONMEM and R were used for analyses.

Results

Typical estimates of clearance, central volume of distribution (V1), an

SUBMITTER: Han K 

PROVIDER: S-EPMC4693565 | biostudies-literature | 2016 Jan

REPOSITORIES: biostudies-literature